Literature DB >> 2456581

Differential loss of striatal projection neurons in Huntington disease.

A Reiner1, R L Albin, K D Anderson, C J D'Amato, J B Penney, A B Young.   

Abstract

Huntington disease (HD) is characterized by the loss of striatal projection neurons, which constitute the vast majority of striatal neurons. To determine whether there is differential loss among different populations of striatal projection neurons, the integrity of the axon terminal plexuses arising from the different populations of substance P-containing and enkephalin-containing striatal projection neurons was studied in striatal target areas by immunohistochemistry. Analysis of 17 HD specimens indicated that in early and middle stages of HD, enkephalin-containing neurons projecting to the external segment of the globus pallidus were much more affected than substance P-containing neurons projecting to the internal pallidal segment. Furthermore, substance P-containing neurons projecting to the substantia nigra pars reticulata were more affected than those projecting to the substantia nigra pars compacta. At the most advanced stages of the disease, projections to all striatal target areas were depleted, with the exception of some apparent sparing of the striatal projection to the substantia nigra pars compacta. These findings may explain some of the clinical manifestations and pharmacology of HD. They also may aid in identifying the neural defect underlying HD and provide additional data with which to evaluate current models of HD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456581      PMCID: PMC281835          DOI: 10.1073/pnas.85.15.5733

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat.

Authors:  R M Beckstead; C J Cruz
Journal:  Neuroscience       Date:  1986-09       Impact factor: 3.590

2.  Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease.

Authors:  P C Emson; A Arregui; V Clement-Jones; B E Sandberg; M Rossor
Journal:  Brain Res       Date:  1980-10-13       Impact factor: 3.252

3.  Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.

Authors:  S H Buck; T F Burks; M R Brown; H I Yamamura
Journal:  Brain Res       Date:  1981-03-30       Impact factor: 3.252

4.  Light and electron microscopic localization of immunoreactive Leu-enkephalin in the monkey basal ganglia.

Authors:  M DiFiglia; N Aronin; J B Martin
Journal:  J Neurosci       Date:  1982-03       Impact factor: 6.167

5.  Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry.

Authors:  S N Haber; W J Nauta
Journal:  Neuroscience       Date:  1983-06       Impact factor: 3.590

6.  Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.

Authors:  P E Marshall; D M Landis; E L Zalneraitis
Journal:  Brain Res       Date:  1983-12-19       Impact factor: 3.252

7.  A polymorphic DNA marker genetically linked to Huntington's disease.

Authors:  J F Gusella; N S Wexler; P M Conneally; S L Naylor; M A Anderson; R E Tanzi; P C Watkins; K Ottina; M R Wallace; A Y Sakaguchi
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

8.  Distribution of enkephalin-related peptides in rat brain: immunohistochemical studies using antisera to met-enkephalin and met-enkephalin Arg6Phe7.

Authors:  R G Williams; G J Dockray
Journal:  Neuroscience       Date:  1983-07       Impact factor: 3.590

9.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

Authors:  E G Spokes
Journal:  Brain       Date:  1980-03       Impact factor: 13.501

10.  Morphometric studies of the neuropathological changes in choreatic diseases.

Authors:  H Lange; G Thörner; A Hopf; K F Schröder
Journal:  J Neurol Sci       Date:  1976-08       Impact factor: 3.181

View more
  278 in total

1.  Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

Authors:  H Awad; G W Hubert; Y Smith; A I Levey; P J Conn
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Identification of the anterior nucleus of the ansa lenticularis in birds as the homolog of the mammalian subthalamic nucleus.

Authors:  Y Jiao; L Medina; C L Veenman; C Toledo; L Puelles; A Reiner
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.

Authors:  Isabel Lastres-Becker; María Gómez; Rosario De Miguel; José A. Ramos; Javier Fernández-Ruiz
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  Sodium selenite protects from 3-nitropropionic acid-induced oxidative stress in cultured primary cortical neurons.

Authors:  Dirleise Colle; Danúbia Bonfanti Santos; Viviane de Souza; Mark William Lopes; Rodrigo Bainy Leal; Patricia de Souza Brocardo; Marcelo Farina
Journal:  Mol Biol Rep       Date:  2018-12-03       Impact factor: 2.316

5.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

6.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

8.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

10.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.